keyword
MENU ▼
Read by QxMD icon Read
search

Nonsmall cell lung ca

keyword
https://www.readbyqxmd.com/read/29767438/serum-sp70-is-a-sensitive-predictor-of-chemotherapy-response-in-patients-with-advanced-nonsmall-cell-lung-cancer
#1
Jingping Liu, Wei Zhang, Min Gu, Yazhou Ji, Lu Yang, Xiangjun Cheng, Xuelian Xiao, Jian Xu, Chunrong Gu, Jiexin Zhang, Shichang Zhang, Dan Chen, Shiyang Pan
SP70 is a novel tumor biomarker in patients with nonsmall cell lung cancer (NSCLC). However, its role as a marker for predicting the response to chemotherapy for patients with advanced NSCLC has not been investigated. A total of 152 patients were enrolled. Serum SP70, carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), and neuron-specific enolase (NSE) were detected before and after 2 cycles of chemotherapy. The correlation between serum tumor biomarker levels and chemotherapy responses and their association with epidermal growth factor receptor (EGFR) mutation status and progression-free survival (PFS) were analyzed...
May 16, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29765975/relationship-of-snp-rs2645429-in-farnesyl-diphosphate-farnesyltransferase-1-gene-promoter-with-susceptibility-to-lung-cancer
#2
Mehdi Dehghani, Zahra Samani, Hassan Abidi, Leila Manzouri, Reza Mahmoudi, Saeed Hosseini Teshnizi, Mohsen Nikseresht
Background and Purpose: The mevalonate pathway is one of the major metabolic pathways that use acetyl-CoA to produce sterols and isoprenoids. These compounds can be effective in the growth and development of tumors. One of the enzymes involved in the mevalonate pathway is FDFT1. Different variants of this gene are involved in the risk of suffering various diseases. The present study examined the relationship between FDFT1 rs2645429 polymorphism and the risk of nonsmall cell lung cancer (NSCLC) in a population from southern Iran...
2018: International Journal of Genomics
https://www.readbyqxmd.com/read/29744296/plasma-anti-birc5-igg-may-be-a-useful-marker-for-evaluating-the-prognosis-of-nonsmall-cell-lung-cancer
#3
Huan Zhao, Xuan Zhang, Zhifeng Han, Zhenqi Wang, Yao Wang
A recent study demonstrated that circulating levels of IgG antibodies against linear peptide antigens derived from baculoviral IAP repeat-containing protein 5 isoform 2 (BIRC5) and myc proto-oncogene protein (MYC) were significantly increased in nonsmall cell lung cancer (NSCLC). This study was undertaken to replicate this initial work in an independent sample. An enzyme-linked immunosorbent assay (ELISA) was developed in-house to examine plasma IgG antibodies for three linear peptide antigens derived from BIRC5a, BIRC5b, and MYC in 211 patients with NSCLC and 200 control subjects...
May 2018: FEBS Open Bio
https://www.readbyqxmd.com/read/29736285/nonsmall-cell-lung-carcinoma-with-giant-cell-features-expressing-programmed-death-ligand-1-a-report-of-a-patient-successfully-treated-with-pembrolizumab
#4
Shingo Nakayama, Mamoru Sasaki, Shojiroh Morinaga, Naoto Minematsu
Giant cell carcinoma, a rare variant of nonsmall cell lung carcinoma (NSCLC), is characterized by aggressive progression and poor response to conventional chemotherapy. This report is the first to describe a patient with NSCLC and giant cell features who was successfully treated with pembrolizumab, an antibody targeting programmed death-1 (PD-1). A 69-year-old woman was diagnosed with NSCLC with multiple brain metastases. Histological evaluation of lung biopsy specimens revealed proliferation of pleomorphic giant tumor cells with poor cohesiveness, findings consistent with giant cell carcinoma...
2018: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/29720822/herbal-medicines-showing-synergistic-effects-with-tumor-necrosis-factor-related-apoptosis-inducing-ligand-trail-against-a549-trail-resistant-lung-cancer-cells-a-screening-study
#5
Shuen Cheng Chiang, Yeon-Jung Choi, Shi-Eun Kang, Miyong Yun, Beom-Joon Lee
Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine that activates apoptosis through death receptors on the cell surface and is regarded as a potential anticancer agent. However, many cancer cells are resistant to TRAIL-induced apoptosis. Objective: The aim is to identify the herbal medicines that could help overcome resistance in TRAIL-resistant lung cancer cells. Materials and Methods: TRAIL-resistant A549 cells and 13 herbal medicines with known apoptosis-related anticancer effects were used in this study: Clematidis Radix , Corydalis Tuber Rhizoma , Paeoniae Radix Rubra , Corni Fructus , Curcumae longae Rhizoma (CLR) , Moutan Cortex , Salviae miltiorrhizae Radix , Phellodendri Cortex , Farfarae Flos , Paeoniae Radix Alba , Angelicae gigantis Radix , Coptidis Rhizoma (CR), and Taraxaci Herba ...
April 2018: Pharmacognosy Magazine
https://www.readbyqxmd.com/read/29696151/effectiveness-of-treatment-with-endostatin-in-combination-with-emcitabine-carboplatin-and-gemcitabine-in-patients-with-advanced-non-small-cell-lung-cancer-a-retrospective-study
#6
Xun Yu, Lemeng Zhang, Jianhua Chen
This study investigated the clinical efficacy, safety and tolerance of endostatin combined with gemcitabine and carboplatin for patients with advanced nonsmall cell lung cancer (NSCLC). From January 2010 to January 2014, 49 patients with advanced NSCLC were retrospectively evaluated; we defined 2 subgroups: a combination group (chemotherapy + anti-angiogenic therapy) and a chemotherapy group (chemotherapy only). The cases in the chemotherapy group received treatment with gemcitabine and carboplatin only, whereas the cases in the combination group received endostatin in combination with gemcitabine and carboplatin...
2018: Open Medicine (Warsaw, Poland)
https://www.readbyqxmd.com/read/29692997/efficacy-of-next-treatment-received-after-nivolumab-progression-in-patients-with-advanced-nonsmall-cell-lung-cancer
#7
Adrien Costantini, Jennifer Corny, Vincent Fallet, Sophie Renet, Sylvie Friard, Christos Chouaid, Boris Duchemann, Etienne Giroux-Leprieur, Laurent Taillade, Ludovic Doucet, Marina Nguenang, Stéphane Jouveshomme, Marie Wislez, Jean Tredaniel, Jacques Cadranel
Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to evaluate the efficacy of nivolumab and of next treatment received after nivolumab progression in patients with advanced NSCLC. Our multicentre retrospective study included all patients receiving nivolumab between January and December 2015. The primary end-point was progression-free survival (PFS) of treatment given after nivolumab...
April 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29692628/the-association-of-polymorphisms-in-mirnas-with-nonsmall-cell-lung-cancer-in-a-han-chinese-population
#8
Chuanyin Li, Yu Zhang, Yingfu Li, Qianli Ma, Shuyuan Liu, Yueting Yao, Fang Tan, Li Shi, Yufeng Yao
Background: MicroRNAs (miRNAs) have been demonstrated to play important roles in cancer progression. Recently, studies have revealed that polymorphisms in miRNAs might be associated with cancer susceptibility. Materials and methods: In the current study, we investigated the associations of single nucleotide polymorphisms (SNPs) in miRNAs (rs11134527 in pri-miR-218-2 , rs74693964 in pri-miR-145 , rs6062251 in pri-miR-133a-2 , and rs4705343 in pri-miR-143 ) with nonsmall cell lung cancer (NSCLC) in a Han population from Yunnan Province, Southwest China using a binary logistic regression analysis...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29692625/histological-subtype-of-lung-cancer-affects-acceptance-of-illness-severity-of-pain-and-quality-of-life
#9
Jacek Polański, Mariusz Chabowski, Beata Jankowska-Polańska, Dariusz Janczak, Joanna Rosińczuk
Introduction: Histologic classification of lung cancer plays an important role in clinical practice. Two main histological subtype of lung cancer: small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC) differ in terms of invasiveness, response to treatment, and risk factors, among others. Aims: To evaluate differences in acceptance of illness, level of perceived pain, and quality of life (QoL) between patients with SCLC and NSCLC. Materials and methods: Two hundred and fifty-seven lung cancer patients, who were treated in 2015, completed Acceptance of Illness Scale, Visual Analog Scale for pain, and European Organization for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire and European Organization for Research and Treatment of Cancer 13-item Lung Cancer specific Quality of Life Questionnaire...
2018: Journal of Pain Research
https://www.readbyqxmd.com/read/29676470/role-of-mirnas-in-lung-cancer
#10
REVIEW
Arif Uddin, Supriyo Chakraborty
Lung cancer (LC) is the leading cause of cancer-related deaths all over the world, among both men and women, with an incidence of over 200,000 new cases per year coupled with a very high mortality rate. LC comprises of two major clinicopathological categories: small-cell (SCLC) and nonsmall-cell lung carcinoma (NSCLC). The microRNAs (miRNAs) are small noncoding RNAs, usually 18-25 nucleotides long, which repress protein translation through binding to complementary target mRNAs. The miRNAs regulate many biological processes including cell cycle regulation, cellular growth, proliferation, differentiation, apoptosis, metabolism, neuronal patterning, and aging...
April 20, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29672399/minimally-invasive-lobectomy-is-associated-with-lower-noncancer-specific-mortality-in-elderly-patients-a-propensity-score-matched-competing-risks-analysis
#11
Boris Hristov, Takashi Eguchi, Sarina Bains, Joe Dycoco, Kay See Tan, James M Isbell, Bernard J Park, David R Jones, Prasad S Adusumilli
OBJECTIVE: To investigate cancer- and noncancer-specific mortality following lobectomy by minimally invasive surgery (MIS) versus open thoracotomy in elderly patients with nonsmall cell lung cancer (NSCLC). BACKGROUND: Two-thirds of patients with NSCLC are ≥65 years of age. As age increases, the risk of competing events, such as noncancer death, also increases. METHODS: Elderly patients (≥65 yrs of age) who have undergone curative-intent lobectomy for stage I-III NSCLC without induction therapy (2002-2013) were included (n=1,303)...
April 18, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29600239/clinical-outcome-study-of-crizotinib-in-immunohistochemistry-proven-echinoderm-microtubule-associated-protein-like-4-anaplastic-lymphoma-kinase-fusion-gene-among-indian-patients-with-adenocarcinoma-lung
#12
Ullas Batra, Mohit Aggarwal, Parveen Jain, Pankaj Goyal, Abhishek Yadav, Udip Maheshwari, Anurag Mehta
Aims: The anaplastic lymphoma kinase (ALK) Break Apart FISH Probe Kit and Ventana anti-ALK (D5F3) CDx immunohistochemistry (IHC) assay are the Food and Drug Administration-approved companion diagnostic for targeted therapy with the ALK inhibitor crizotinib in lung cancers. The aim of this study was to assess the efficacy and safety of twice daily crizotinib tablet (250 mg) in IHC-proven echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene among Indian patients with adenocarcinoma lung in the routine clinical practice...
January 2018: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/29578911/adrenal-metastasectomy-in-the-presence-and-absence-of-extraadrenal-metastatic-disease
#13
Ashley E Russo, Brian R Untch, Mark G Kris, Joanne F Chou, Marinela Capanu, Daniel G Coit, Jamie E Chaft, Michael I D'Angelica, Murray F Brennan, Vivian E Strong
OBJECTIVE: To determine if there are differences in overall survival (OS) or event-free survival (EFS) in patients with and without concomitant extra-adrenal metastases undergoing adrenal metastasectomy. BACKGROUND: There is growing interest in the use of local therapies in patients with oligometastatic disease. Previously published series have indicated that long-term survival is possible with resection. Adrenalectomy has been used to treat adrenal metastases in select patients...
March 23, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29578164/phosphatase-and-tensin-homolog-protein-may-be-linked-to-lymph-node-metastasis-and-tumor-node-metastasis-staging-in-nonsmall-cell-lung-cancer
#14
Zhi-Yong Ji, Hai-Feng Li, Yu Lei, Yan-Wei Rao, Ming-Li Sun, Xin-Wei Wang, Yan-Lin Zhang
Background: This study aims to investigate the correlations of positive rate of phosphatase and tensin homolog (PTEN) protein with lymph node metastasis (LNM) and tumor node metastasis (TNM) staging of nonsmall cell lung cancer (NSCLC) patients by conducted a meta-analysis. Materials and Methods: Covering several electronic databases (Embase, Cochrane Library, China BioMedicine, China National Knowledge Infrastructure, PubMed, and Web of Science), published papers eligible for enrollment in the current meta-analysis had to fulfill our predefined selection criteria...
2018: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29578158/effect-of-spleen-tyrosine-kinase-on-nonsmall-cell-lung-cancer
#15
Ying Tao Hao, Chuan Liang Peng, Yun Peng Zhao, Qi Feng Sun, Xiao Gang Zhao, Bo Cong
Aim of Study: To investigate the anti.tumor effect of spleen tyrosine kinase. (Syk) on the human nonsmall cell lung cancer cells in vitro and its mechanism. Materials and Methods: In this study, we constructed a eukaryotic expression vector pcDNA3.1D/V5-His-TOPO/Syk and transfected it into human nonsmall cell lung cancer cells A549. Then, we not only analyzed the expression of Syk in transfected cells and its invasion but also the expression of matrix metalloproteinase-9 (MMP-9)...
2018: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29578153/dual-specificity-phosphatase-6-genetic-variants-associated-with-risk-of-lung-squamous-cell-carcinoma-in-han-chinese
#16
Tian-Lu Wang, Ying-Qiu Song, Yang-Wu Ren, Bao-Sen Zhou, He-Tong Wang, Ya Gao, Hong Yu, Yu-Xia Zhao
Background: Nonsmall cell lung cancer (NSCLC) mainly contains adenocarcinoma (AC) and squamous cell carcinoma (SqCC). This study investigated single nucleotide polymorphism (SNP) of topoisomerase II alpha (TOP2A) and dual-specificity phosphatase 6 (DUSP6) in a hospital-based case and control cohort of individuals for association with risk of different histological subtypes of NSCLC. Materials and Methods: A total of 454 (237 SqCC and 217 AC) NSCLC patients, and 454 healthy controls were recruited for analysis of TOP2A rs471692 and DUSP6 rs2279574 genotypes using the TaqMan polymerase chain reaction technique...
2018: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29578152/death-associated-protein-kinase-promoter-methylation-correlates-with-clinicopathological-and-prognostic-features-in-nonsmall-cell-lung-cancer-patients-a-cohort-study
#17
Xiao-Yu Yang, Jun Zhang, Xiao-Ling Yu, Guo-Feng Zheng, Fei Zhao, Xiao-Jing Jia
Objective: The objective was to study the correlation between death-associated protein kinase (DAPK) promoter methylation and the clinicopathological and prognostic features in nonsmall cell lung cancer (NSCLC) patients. Materials and Methods: A total of 117 NSCLC patients were recruited into our study between December 2012 and December 2014. Methylation-specific polymerase chain reaction was employed to detect the methylation status of DAPK in cancer tissues, peficancerous tissues, and serum samples of 117 NSCLC patients...
2018: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29578147/comparison-of-the-efficacy-of-strontium-89-chloride-in-treating-bone-metastasis-of-lung-breast-and-prostate-cancers
#18
Xiaojuan Ye, Da Sun, Cen Lou
Objective: The aim of this study was to comparatively evaluate the efficacy of strontium-89 chloride (89 SrCl2 ) in treating bone metastasis-associated pain in patients with lung, breast, or prostate cancer. Materials and Methods: The 126 patients with lung cancer included 88, 16, 15, 4, and 3 patients with adenocarcinoma, squamous cell carcinoma, nonsmall cell carcinoma, mixed carcinoma, and small cell carcinoma, respectively, and the control group consisted of patients with breast (71 patients) or prostate cancer (49 patients) who underwent89 SrCl2 treatment during the same period...
2018: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29573236/efficacy-safety-and-predictive-indicators-of-apatinib-after-multilines-treatment-in-advanced-nonsquamous-nonsmall-cell-lung-cancer-apatinib-treatment-in-nonsquamous-nsclc
#19
Di Wu, Li Liang, Ligong Nie, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Tao Xin, Jian Fang
AIM: Patients with advanced nonsquamous nonsmall cell lung cancer (NSCLC) who experienced progression with two or more lines chemotherapy have no treatment options that clearly confer a survival benefit. As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, apatinib has a certain antitumor effect for various solid tumors. The present study evaluated the efficacy and safety of apatinib in advanced nonsquamous NSCLC as salvage treatment in Chinese real-world practice...
March 24, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29567880/myeloid-cell-leukemia-1-protein-expression-and-myeloid-cell-leukemia-1-gene-amplification-in-non-small-cell-lung-cancer
#20
Tony El Jabbour, Siddhartha Dilip Dalvi, Sungeun Kim, Christine Sheehan, Jeffrey S Ross
Background: Myeloid cell leukemia-1 (Mcl-1) is a member of the B-cell lymphoma 2 family known to play a significant role in the regulation of apoptosis. Mcl-1 expression has been studied in nonsmall cell lung cancer (NSCLC) cell lines but has not been previously evaluated as a prognostic factor in clinical samples. Materials and Methods: Formalin-fixed, paraffin-embedded sections from 119 NSCLC, including 33 squamous cell carcinomas (SCC), 55 adenocarcinomas (AC), and 31 either pure adenocarcinoma in situ (AIS) or AC with lepidic features were immunostained by an automated method with rabbit polyclonal Mcl-1...
January 2018: Indian Journal of Pathology & Microbiology
keyword
keyword
13799
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"